These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
419 related articles for article (PubMed ID: 35383908)
21. Efficacy and Safety of Nivolumab and Ipilimumab for Advanced or Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Cohort Study. Iinuma K; Kameyama K; Kawada K; Fujimoto S; Takagi K; Nagai S; Ito H; Ishida T; Kawase M; Kawase K; Nakai C; Kato D; Takai M; Nakane K; Koie T Curr Oncol; 2021 Apr; 28(2):1402-1411. PubMed ID: 33916792 [TBL] [Abstract][Full Text] [Related]
22. The Relationship Between Health-Related Quality of Life and Overall Survival in Patients With Advanced Renal Cell Carcinoma in CheckMate 214. Cella D; Choueiri TK; Hamilton M; Blum SI; Ivanescu C; Karu K; Ejzykowicz F; Motzer RJ Oncologist; 2024 Jun; 29(6):511-518. PubMed ID: 38280218 [TBL] [Abstract][Full Text] [Related]
23. Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial. Cella D; Grünwald V; Escudier B; Hammers HJ; George S; Nathan P; Grimm MO; Rini BI; Doan J; Ivanescu C; Paty J; Mekan S; Motzer RJ Lancet Oncol; 2019 Feb; 20(2):297-310. PubMed ID: 30658932 [TBL] [Abstract][Full Text] [Related]
24. Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study. Amin A; Plimack ER; Ernstoff MS; Lewis LD; Bauer TM; McDermott DF; Carducci M; Kollmannsberger C; Rini BI; Heng DYC; Knox J; Voss MH; Spratlin J; Berghorn E; Yang L; Hammers HJ J Immunother Cancer; 2018 Oct; 6(1):109. PubMed ID: 30348216 [TBL] [Abstract][Full Text] [Related]
25. Comparison of nivolumab plus ipilimumab with tyrosine kinase inhibitors as first-line therapies for metastatic renal-cell carcinoma: a multicenter retrospective study. Kido K; Hatakeyama S; Numakura K; Tanaka T; Oikawa M; Noro D; Hosogoe S; Narita S; Inoue T; Yoneyama T; Ito H; Nishimura S; Hashimoto Y; Kawaguchi T; Habuchi T; Ohyama C Int J Clin Oncol; 2021 Jan; 26(1):154-162. PubMed ID: 33067647 [TBL] [Abstract][Full Text] [Related]
26. Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial. Regan MM; Jegede OA; Mantia CM; Powles T; Werner L; Motzer RJ; Tannir NM; Lee CH; Tomita Y; Voss MH; Plimack ER; Choueiri TK; Rini BI; Hammers HJ; Escudier B; Albiges L; Huo S; Del Tejo V; Stwalley B; Atkins MB; McDermott DF Clin Cancer Res; 2021 Dec; 27(24):6687-6695. PubMed ID: 34759043 [TBL] [Abstract][Full Text] [Related]
27. Bempegaldesleukin Plus Nivolumab Versus Sunitinib or Cabozantinib in Previously Untreated Advanced Clear Cell Renal Cell Carcinoma: A Phase III Randomized Study (PIVOT-09). Tannir NM; Formiga MN; Penkov K; Kislov N; Vasiliev A; Gunnar Skare N; Hong W; Dai S; Tang L; Qureshi A; Zalevsky J; Tagliaferri MA; George D; Agarwal N; Pal S J Clin Oncol; 2024 Aug; 42(23):2800-2811. PubMed ID: 38838287 [TBL] [Abstract][Full Text] [Related]
28. Primary resistance to nivolumab plus ipilimumab therapy in patients with metastatic renal cell carcinoma. Numakura K; Sekine Y; Hatakeyama S; Muto Y; Sobu R; Kobayashi M; Sasagawa H; Kashima S; Yamamto R; Nara T; Akashi H; Tabata R; Sato S; Saito M; Narita S; Ohyama C; Habuchi T Cancer Med; 2023 Aug; 12(16):16837-16845. PubMed ID: 37403728 [TBL] [Abstract][Full Text] [Related]
29. Ipilimumab and nivolumab combined with anthracycline-based chemotherapy in metastatic hormone receptor-positive breast cancer: a randomized phase 2b trial. Andresen NK; Røssevold AH; Quaghebeur C; Gilje B; Boge B; Gombos A; Falk RS; Mathiesen RR; Julsrud L; Garred Ø; Russnes HG; Lereim RR; Chauhan SK; Lingjærde OC; Dunn C; Naume B; Kyte JA J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38242720 [TBL] [Abstract][Full Text] [Related]
30. A matching-adjusted indirect comparison of combination nivolumab plus ipilimumab with BRAF plus MEK inhibitors for the treatment of BRAF-mutant advanced melanoma Tarhini AA; Toor K; Chan K; McDermott DF; Mohr P; Larkin J; Hodi FS; Lee CH; Rizzo JI; Johnson H; Moshyk A; Rao S; Kotapati S; Atkins MB ESMO Open; 2021 Apr; 6(2):100050. PubMed ID: 33556898 [TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of subsequent molecular targeted therapy after immuno-checkpoint therapy, retrospective study of Japanese patients with metastatic renal cell carcinoma (AFTER I-O study). Tomita Y; Kimura G; Fukasawa S; Numakura K; Sugiyama Y; Yamana K; Naito S; Kabu K; Tajima Y; Oya M Jpn J Clin Oncol; 2021 May; 51(6):966-975. PubMed ID: 33594427 [TBL] [Abstract][Full Text] [Related]
32. Comparative Effectiveness of Front-Line Ipilimumab and Nivolumab or Axitinib and Pembrolizumab in Metastatic Clear Cell Renal Cell Carcinoma. Zarrabi KK; Handorf E; Miron B; Zibelman MR; Anari F; Ghatalia P; Plimack ER; Geynisman DM Oncologist; 2023 Feb; 28(2):157-164. PubMed ID: 36200791 [TBL] [Abstract][Full Text] [Related]
33. Long-term comparative efficacy and safety of nivolumab plus ipilimumab relative to other first-line therapies for advanced non-small-cell lung cancer: A systematic literature review and network meta-analysis. O'Byrne K; Popoff E; Badin F; Lee A; Yuan Y; Lozano-Ortega G; Eccles LJ; Varol N; Waser N; Penrod JR; Goring S Lung Cancer; 2023 Mar; 177():11-20. PubMed ID: 36669321 [TBL] [Abstract][Full Text] [Related]
34. Evaluating the efficacy and safety of nivolumab and ipilimumab combination therapy compared to nivolumab monotherapy in advanced cancers (excluding melanoma): a systemic review and meta-analysis. Rangwala HS; Fatima H; Ali M; Sunder S; Devi S; Rangwala BS; Abbas SR J Egypt Natl Canc Inst; 2024 May; 36(1):14. PubMed ID: 38705953 [TBL] [Abstract][Full Text] [Related]
35. Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study. Callahan MK; Kluger H; Postow MA; Segal NH; Lesokhin A; Atkins MB; Kirkwood JM; Krishnan S; Bhore R; Horak C; Wolchok JD; Sznol M J Clin Oncol; 2018 Feb; 36(4):391-398. PubMed ID: 29040030 [TBL] [Abstract][Full Text] [Related]
36. Efficacy of Nivolumab plus Ipilimumab According to Number of IMDC Risk Factors in CheckMate 214. Escudier B; Motzer RJ; Tannir NM; Porta C; Tomita Y; Maurer MA; McHenry MB; Rini BI Eur Urol; 2020 Apr; 77(4):449-453. PubMed ID: 31732098 [TBL] [Abstract][Full Text] [Related]
37. Subgroup analysis of the AFTER I-O study: a retrospective study on the efficacy and safety of subsequent molecular targeted therapy after immune-oncology therapy in Japanese patients with metastatic renal cell carcinoma. Tomita Y; Kimura G; Fukasawa S; Numakura K; Sugiyama Y; Yamana K; Naito S; Kaneko H; Tajima Y; Oya M Jpn J Clin Oncol; 2021 Nov; 51(11):1656-1664. PubMed ID: 34350454 [TBL] [Abstract][Full Text] [Related]